secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2026-08-04T20:03:29+00:00
Accession:  0001386570-26-000042
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience Q2 net sales $29.8M, net income $1.0M; launches pharmaceutical program targeting rare diseases
--------------------------------------------------------------------------------

- Net sales $29.8M ($24.2M Tru Niagen); gross margin 64.8%; net income $1.0M ($0.01 EPS); adjusted EBITDA $3.0M.
- Launched Niagen Plus telehealth platform with at-home injection kit; received LegitScript certification for advertising.
- Introduced NB4168 for rare genetic diseases targeting Ataxia-Telangiectasia; received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations.
- Appointed Abhijit Kale as Senior Director of Global External Research to lead pharmaceutical program.
- 2026 outlook: e-commerce growth 10-15% YoY; ingredient business expected lower; expects increased operating expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/0001386570-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001386570-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer